GSK Investigator-sponsored studies programme





GSK Investigator Sponsored Studies

Our mission

At GSK, we are dedicated to improving the quality of human life by enabling people to do more, feel better and live longer. As part of this commitment, we recognise the valuable role that our support of Investigator-sponsored studies (ISS) plays in fulfilling this mission.

An investigator sponsored study is research conducted by an external Sponsor, with GSK’s support. The Sponsor of the study is an external investigator, healthcare institution, or medical network and is seeking support from GSK to conduct the study which can be in the form of funding, drug product (including GSK products, adjuvant for vaccines, placebo, or other medicinal products necessary for the research), or both.

The decision to support a study is based on:

  • The importance and innovation of the research objectives to medical science or patient care
  • Alignment with GSK’s current areas of interest, and
  • The ability of the study Sponsor to deliver a high-quality ethical study
  • Assessment of the resource request matched against what GSK has available

We do not support ISS in order to reward healthcare professionals for using, purchasing, recommending, or prescribing GSK products or to persuade them to do so. GSK is not committed to provide support (product or funding) until a legal agreement has been signed by both parties.

Areas of Interest

Please find below the current area of interest per therapy area. These may be updated ahead of each submission area:

  • Vaccines

  • Pharma

  • Consumer Healthcare

  • Submission timelines

    GSK is committed to responding to your Proposal within 8 weeks from the closing date. Please find below the next submission and review dates for submitted proposals within each Therapy Area.

    This is a step change for GSK. Following feedback from our external partners on the ISS process, we are refining our ISS submission process, to enable us to review and respond to proposals in an accelerated and more effective manner; and select proposals that best advance science and patient care. We welcome your ongoing feedback.

    Therapeutic Area Proposal submission period opens Proposal submission period close Proposal of Interest communication date Further Information
    Vaccines Opens on 1 December 2018 28 February 2019 11 April 2019 The call for Proposal is for Human Subject Research ISS at this time
    Pharma - Immunology, Inflammation and Future Pipeline (belimumab) Open for submission 31 January 2019 31 March 2019
    Pharma – Respiratory Opens May 2019 20 July 2019 September 2019 GSK is redefining its supported studies (investigator sponsored studies and supportive collaborative studies) submission process to an annual Call for Proposal model in the area of Respiratory medicine, to enable us to review and respond to proposals in an accelerated and more effective manner; and select proposals that best advance science and patient care. We will issue an update in December 2018 with information on the exact dates for the call, our areas of interest and when you will receive a response back from us.
    For any queries please reach out to your local Medical point of contact.
    We recognise the implication this may have on your plans and we thank you for your patience.
    Pharma - Classic and Established Products (Marketed Products) Opens 1 December 2018 27 January 2019 24 March 2019
    Pharma – Oncology Opens March 2019 GSK is moving fast to expand in Oncology therefore we are redefining our supported studies submission process to a regular review process. The submission window for Oncology ISS is currently closed and no funding decisions on proposals already submitted will be made until 31st May 2019. We will issue an update in February 2019 with information on the exact dates for the submission windows, our areas of interest and when you will receive a response back from us.
    We recognise the implication this may have on your plans and we thank you for your patience.
    Consumer Healthcare Opens 7 January 2019 29 March 2019 10 May 2019

    Although GSK are more likely to support studies aligned to our current areas of interest for supported studies, we are interested in supporting studies that are innovative and contribute to scientific knowledge relating to a product, a medical condition or advancing a technology that supports human subject research.

    Sponsors can request access to anonymised patient-level data from GSK sponsored clinical studies via the following link: https://clinicalstudydatarequest.com/

Notification on belimumab proposals:

New investigator study proposals, within our current areas of interest, may be submitted up to 31st of January 2019 and will be reviewed by the belimumab ISS Committee in the next review cycle in Q1-2019. Review decisions will be communicated by Q2-2019. Decisions will be made on the basis of legitimate scientific purpose and the ability of the investigator to deliver a high-quality, ethical study. Please click on this link if you would like to know more about it.

Submit your proposal

Notification to all users:

For more information on HIV/AIDS research by ViiV and ISS programme, please contact your ViiV Healthcare representative. For ALL ISS proposals to GSK Vaccines (including HIV disease), please follow GSK process in this website.

Browser Requirements

Click here to view browser requirements for this portal.

Tell us how we are doing!



Terms of use Accessibility Cookie policy Privacy
© 2001-2018 GlaxoSmithKline plc. All rights reserved. Registered in England and Wales No. 3888792.
Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.